Skip to content

Tonix to present PTSD med Phase 2 data

May 19, 2017

Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced it will present additional analyses of data from its Phase 2 study in military-related posttraumatic stress disorder, or PTSD, at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) on May 20, 2017 in San Diego.

Gregory Sullivan, M.D., chief medical officer of Tonix, will present moderators and mediators analyses from Tonix’s Phase 2 AtEase study of TNX-102 SL*. TNX-102 SL is the first PTSD drug candidate designated by the U.S. Food and Drug Administration (FDA) as a Breakthrough Therapy. A moderator is a characteristic of participants going into the study that is associated with a response to treatment, while a mediator is a clinical finding that the response to therapy may depend on, such as sleep quality. Details of the poster presentation follow.

Title: Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder: Mediators and Moderators of Treatment Response (Poster No. 3001130)
Date: Saturday, May 20, 2017
Time:  5-7 p.m. PDT
Location:  Sapphire CP, Hilton San Diego Bayfront

*TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: